Piotr Kuszmiersz
Country: Poland
Piotr is a PhD in Medical Sciences and an Internal Medicine Specialist, currently undertaking his rheumatology training at the Department of Rheumatology and Immunology, Jagiellonian University Medical College in Kraków, Poland. His research interests focus on Patient-Reported Outcome Measures, epidemiology, and the application of AI in medicine. Piotr is a member of the EMEUNET Social Media Sub-Committee.
| Oral 0089 | Wednesday 11.06.25 16:30-16:40 PM Clinical Abstract Sessions: Shaping the Future of Psoriatic Arthritis Treatment Author: L.C. Coates (United Kingdom) Title: Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step-up care for the treatment of moderate-to-severe psoriatic arthritis: the 3-arm parallel group SPEED RCT  The SPEED trial demonstrates that initial intensive therapy with early biologics or combination DMARDs provides superior disease control compared to standard step-up care in early moderate-severe psoriatic arthritis patients with poor prognostic factors. Benefits from early TNF inhibitor therapy persisted at one year, supporting a more aggressive initial treatment approach. |
| Poster 0017 | Wednesday 11.06.25 16:12-16:18 PM Basic Poster Tours: New molecules on the horizon in Spondyloarthritis and Psoriatic Arthritis Author: M.F. Konig (USA) Title: Bispecific T Cell-Engaging Antibodies to Target TRBV9+ Autoreactive T Cells in Axial Spondyloarthritis Researchers engineered a TRBV9 × CD3 bispecific antibody that selectively redirects cytotoxicity toward TRBV9-expressing T cells—the pathogenic clone in HLA-B27⁺ axSpA—while sparing >95 % of the T-cell repertoire. Ex-vivo and patient-cell data show potent, dose-dependent depletion of autoreactive clones with minimal cytokine release, heralding a precision-immunotherapy strategy. |
| Poster 0905 | Thursday 12.06.25 14:45-15:45 PM Session: Poster View IV Author: X. Baraliakos (Germany) Title: Early meaningful improvements in spinal pain and correlation with other clinical outcomes in patients treated with filgotinib for radiographic axial spondyloarthritis: A post hoc analysis of the Phase 2 TORTUGA trial Post hoc analysis of the TORTUGA trial demonstrates rapid and significant improvements in spinal pain with filgotinib treatment, evident within 2 weeks in r-axSpA patients. Pain reduction correlated strongly with improvements in fatigue, physical function, and quality of life, suggesting JAK inhibition affects both nociceptive and non-nociceptive pain mechanisms. |
| Oral 0383 | Friday 13.06.25 11:10-11:20 AM HPR Abstract Sessions: Physical Activity and Exercise in RMDs – New Insights from Research and Clinical Trials Author: D. Ueckert (Netherlands) Title: Sustained effects of longstanding supervised exercise therapy in rheumatoid arthritis and axial spondyloarthritis patients with severe functional limitations: long-term follow-up This long-term follow-up study shows that personalized, supervised exercise therapy maintains significant improvements in physical function and quality of life two years after initiation in RA and axSpA patients with severe functional limitations. Benefits persisted despite declining therapy usage in the second year, highlighting the sustained value of structured exercise programs. |
| Poster 0235 | Friday 13.06.25 15:21-15:27 PM Basic Poster Tours: Molecular treatment signatures in Spondyloarthridities including Psoriatic Arthritis Author: J. Xie (China) Title: Multi-omics Analysis Reveals Cellular and Molecular Map Linked to Pharmacological Effects and Therapeutic Efficacy of IL-17A Inhibitor in Ankylosing Spondylitis This pioneering multi-omics study identifies that upregulation of interferon-stimulated genes and JAK-STAT pathway abnormalities predict non-response to IL-17A inhibitors in ankylosing spondylitis. LAMP3 and HSD11B1 emerged as potential biomarkers for treatment response, advancing personalized medicine approaches for AS patients. |